Skip to content

Precigen PGEN Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Gilead Sciences logo
Gilead SciencesGILD
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Roivant Sciences logo
Roivant SciencesROIV
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's common stock, shares authorized (in shares)?
Precigen (PGEN) reported common stock, shares authorized (in shares) of $700M in Q1 2026.
How has Precigen's common stock, shares authorized (in shares) changed year-over-year?
Precigen's common stock, shares authorized (in shares) increased by 75.0% year-over-year, from $400M to $700M.
What is the long-term trend for Precigen's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Precigen's common stock, shares authorized (in shares) has grown at a 11.8% compound annual growth rate (CAGR), from $400M to $700M.